Patents by Inventor Brendan Larder

Brendan Larder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
    Publication number: 20030190603
    Abstract: A method and system for predicting the resistance of a disease to a therapeutic agent is provided. Further provided is a method and system for designing a therapeutic treatment agent for a patient afflicted with a disease. Specifically, the methods use a trained neural network to interpret genotypic information obtained from the disease. The trained neural network is trained using a database of known or determined genotypic mutations that are correlated with phenotypic therapeutic agent resistance. The present invention also provides methods and systems for predicting the probability of a patient developing a genetic disease. A trained neural network for making such predictions is also provided. Also provided is a method and system for determining the genetic basis of therapeutic agent resistance.
    Type: Application
    Filed: June 2, 2003
    Publication date: October 9, 2003
    Inventors: Brendan Larder, Dechao Wang
  • Methods for measuring therapy resistance
    Publication number: 20020091664
    Abstract: The present invention concerns methods for measuring drug resistance by correlating genotypic information with phenotypic profiles. In one embodiment, a method for interpreting genotypic information is described wherein a genetic code is generated from a patient sample, a list of mutations known or suspect to play a role in the development of resistance to one or more drugs is obtained from the generated genetic code, a genotype database is interrogated for previous samples with similar mutations relating to said one or more drugs, a phenotype for said sample is located in a phenotype database, the mean change in inhibition is determined based on all the examples located in said phenotype database, a distribution of sensitivities of one or more drugs suitable for treating a specific indication is determined.
    Type: Application
    Filed: April 18, 2001
    Publication date: July 11, 2002
    Inventors: Brendan Larder, Stuart Bloor, Kurt Hertogs, Pascale Alfons Rosa Dehertogh, Rudy Jean Marc Mortier
  • Nucelic acid derivatives
    Patent number: 5409810
    Abstract: This invention relates to a methodology for assessing the sensitivity of an HIV-1 sample to zidovudine and to diagnostic assays for use in such assessment.
    Type: Grant
    Filed: December 1, 1992
    Date of Patent: April 25, 1995
    Assignee: Burroughs Wellcome Co.
    Inventors: Brendan A. Larder, Sharon D. Symons
  • Nucleic acid derivatives
    Patent number: RE37918
    Abstract: This invention relates to a methodology for assessing the sensitivity of an HIV-1 sample to zidovudine and to diagnostic assays for use in such assessment.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: December 3, 2002
    Assignee: Glaxo Wellcome, Inc.
    Inventors: Brendan A. Larder, Sharon D. Kemp nee Symons